Skip to main content
OB

OmniBRx Biotechnologies

OmniBRx Biotechnologies manufactures single-use bioreactors utilizing dynamic-bed reactor (DBR) technology, designed for high-cell density cultures in biologics production and stem cell therapies. Their systems enhance nutrient homogeneity and reduce operational costs, enabling efficient scaling from 0.5L to 200L while meeting stringent regulatory compliance standards.

Ahmedabad, IndiaFounded 2016483K+ followers
Updated 20 months ago

Funding

$3.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

SV
Funding rounds are not available yet.

Founders

Product

Problem

Traditional cell culture methods for biologics production and stem cell therapies often suffer from limitations in scalability, nutrient homogeneity, and cost-effectiveness, hindering efficient production and process economics. Existing technologies may lack the ability to provide sufficient surface area for cell attachment and growth while maintaining homogenous mixing of media and nutrients.

Solution

OmniBRx Biotechnologies offers CellBRx single-use bioreactors that leverage dynamic-bed reactor (DBR) technology to address the challenges of high-cell density cultures. The CellBRx bioreactors combine single-use technologies with the benefits of a dynamic-bed reactor, simplifying adherent cell culture processes. The unique geometry of the bioreactor ensures efficient mixing and mass transfer, promoting nutritional homogeneity within the culture vessel. This DBR technology enables scalable culture from 0.5L to 200L, reducing capital expenditures, labor, and facility costs while increasing protein/cell yield.

Target Audience

The primary target audience includes manufacturers of biologics, vaccines, and stem cell therapeutics, as well as researchers in human genetics, gene therapy, and tissue engineering.

Features

  • Fully integrated perfusion-driven bioreactors designed for high-cell density cultures
  • Dynamic-bed reactor technology ensures efficient mixing and mass transfer
  • Scalable from 0.5L to 200L culture volume
  • Pre-sterilized, pre-validated, and customizable manufacturing
  • Pre-calibrated sensors for pH, dissolved oxygen, temperature, and other metabolites (optional)
  • Integrated perfusion logic and robust automation software
  • Compliant with 21 CFR Part 11 and GMP regulations
  • Optional secured cloud-based data logging for online monitoring and visualization
  • Ethernet/Wi-Fi connectivity for data communication and acquisition
This profile is AI-generated and may contain inaccuracies.